Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | POLA1 | P09884 | 2/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742409 | 0.82 | ADRA2A (0.38) | KDM1AADRA2ALMNACYP3A4CYP2C19 | |
| SCHEMBL3463695 | 0.68 | KDM1A (0.43) | KDM1AADRA2ALMNACYP3A4CYP2C19 | |
| SCHEMBL1495858 | 0.64 | KDM1A (0.53) | KDM1AADRA2ACYP3A4DRD2DRD3 | |
| SCHEMBL4640481 | 0.62 | KDM1A (0.61) | KDM1AADRA2ALMNACYP2C19DRD2 | |
| Hydrochloric Acid SCHEMBL23421993 | 0.62 | KDM1A (0.50) | KDM1AADRA2ACYP3A4DRD2DRD3 | |
| SCHEMBL3465309 | 0.60 | KDM1A (0.43) | KDM1AADRA2ACYP3A4CYP2C19DRD2 | |
| SCHEMBL3464559 | 0.60 | KDM1A (0.46) | KDM1AADRA2ACYP3A4CYP2C19DRD2 | |
| SCHEMBL19520534 | 0.60 | SMN1; SMN2 (0.56) | KDM1AADRA2ALMNACYP3A4CYP2C19 | |
| SCHEMBL19469553 | 0.60 | SMN1; SMN2 (0.56) | KDM1AADRA2ALMNACYP3A4CYP2C19 | |
| SCHEMBL19469571 | 0.60 | SMN1; SMN2 (0.56) | KDM1AADRA2ALMNACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | KDM1A 2819/4885ADRA2A 379/4885LMNA 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.